Ocular antibody-drug conjugates
AssigneeADS Therapeutics LLC
InventorsJinsong NI, Rong YANG, Wenkui Ken FANG
Life of this patent
Estimating the term…
Abstract
An ocular antibody-drug conjugate compound is provided. The compound includes an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; a small molecule drug including an alpha agonist or an anti-inflammatory small molecule selected from a steroid, a NSAID, that regulates a second or more target in the subject; and a linker linking the antibody and the small molecule drug. Methods of treating an ocular disease with the antibody drug conjugate compound are also provided. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the steroid exert their functions simultaneously.
Claims19
A compound comprising:
- an antibody or engineered biologic molecule that blocks VEGF, VEGFR, PDGF, PDGFR, FGF, or FGFR;
- a small molecule drug, the small molecular drug being an adrenergic receptor alpha agonist or an anti-inflammatory small molecule, the anti-inflammatory small molecule being a steroid or a non-steroid anti-inflammatory drug (NSAID);
- and
- a linker that links the small molecule drug to the antibody or engineered biologic molecule,
- wherein the linker comprises a bond that can be hydrolyzed in ocular tissue in a controlled release fashion.
Dependencies are inferred from the claim text.